Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing. A variety of organisms, including bacteria, viruses and fungi, can cause pneumonia.

The global Pneumonia Treatment Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Pneumonia Treatment Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pneumonia Treatment Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pneumonia Treatment Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pneumonia Treatment Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline
MSD
Mylan
Novartis
Pfizer
Teva Pharmaceutical
Arsanis
AstraZeneca
Combioxin
Shinogi
Sun Pharmaceutical
Teva Pharmaceutical
Medicines
Theravance Biopharma

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Macrolides
Cephalosporin
Penicillin
Tetracyclines
Fluoroquinolones
Vancomycin
Other Antibiotics
Immunotherapy Drug
Vaccines
Interferon

Segment by Application
Hospital
Clinic
Drugstore